KASINGER JAMES R.
SEC CIK 1708172 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | GC, Sec | 105.2K | — | $2.70M | 37 | 2021-09-10 | 2026-09-22 |
Most active insiders at CRSP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Kulkarni Samarth | CEO, Dir | — | $10.76M |
| 2 | Prasad Raju | CFO | — | $5.10M |
| 3 | KASINGER JAMES R. | GC, Sec | — | $1.27M |
| 4 | Behbahani Ali | Dir | — | $780.9K |
| 5 | Patel Naimish | Chief Medical Off | — | $362.6K |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-24 17:35 | 2026-09-22 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | $13.62 | +10.4K | 105.2K | +11% | +$141.6K |
| DT | 2026-09-24 17:35 | 2026-09-22 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $60.24 | -10.4K | 94.8K | -10% | -$626.5K |
| D | 2026-03-24 | 2026-03-20 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +6,250 | 97.5K | +7% | — |
| D | 2026-03-24 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $46.78 | -3,182 | 94.3K | -3% | -$148.9K |
| D | 2026-03-17 | 2026-03-14 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +6,875 | 94.7K | +8% | — |
| D | 2026-03-17 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $48.26 | -3,450 | 91.2K | -4% | -$166.5K |
| D | 2026-03-12 | 2026-03-10 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +5,500 | 90.6K | +6% | — |
| D | 2026-03-12 | 2026-03-11 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $52.80 | -2,800 | 87.8K | -3% | -$147.8K |
| D | 2026-02-20 | 2026-02-18 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +3,825 | 87.2K | +5% | — |
| D | 2026-02-20 | 2026-02-19 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $52.58 | -2,112 | 85.1K | -2% | -$111.0K |
| D | 2025-10-15 | 2025-10-14 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $66.60 | -1,076 | 83.4K | -1% | -$71.7K |
| D | 2025-10-15 | 2025-10-13 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +2,114 | 84.5K | +3% | — |
| D | 2025-03-24 | 2025-03-20 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +6,250 | 84.9K | +8% | — |
| D | 2025-03-24 | 2025-03-21 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $41.23 | -3,185 | 81.7K | -4% | -$131.3K |
| DM | 2025-03-12 | 2025-03-11+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $42.67 | -3,966 | 77.5K | -5% | -$169.2K |
| DM | 2025-03-12 | 2025-03-10+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +7,750 | 80.4K | +11% | — |
| DM | 2025-02-19 | 2025-02-16+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +23.8K | 76.8K | +45% | — |
| DM | 2025-02-19 | 2025-02-18+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $53.67 | -11.5K | 73.0K | -14% | -$619.5K |
| D | 2024-10-15 | 2024-10-13 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +2,113 | 63.7K | +3% | — |
| D | 2024-10-15 | 2024-10-14 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $46.28 | -1,089 | 62.6K | -2% | -$50.4K |
| DM | 2024-03-12 | 2024-03-11+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $77.15 | -3,947 | 60.1K | -6% | -$304.5K |
| DM | 2024-03-12 | 2024-03-10+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +7,750 | 62.9K | +14% | — |
| D | 2024-02-21 | 2024-02-18 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +3,825 | 59.3K | +7% | — |
| D | 2024-02-21 | 2024-02-20 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $79.67 | -1,913 | 57.4K | -3% | -$152.4K |
| DM | 2023-03-14 | 2023-03-10+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +5,083 | 54.9K | +10% | — |
| DM | 2023-03-14 | 2023-03-13 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $43.22 | -2,305 | 53.6K | -4% | -$99.6K |
| D | 2023-02-22 | 2023-02-18 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +3,825 | 54.0K | +8% | — |
| D | 2023-02-22 | 2023-02-21 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $48.26 | -1,950 | 52.1K | -4% | -$94.1K |
| D | 2022-12-06 | 2022-12-05 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $52.26 | -3,234 | 50.2K | -6% | -$169.0K |
| D | 2022-12-06 | 2022-12-03 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +6,667 | 53.4K | +14% | — |
| DM | 2022-03-14 | 2022-03-11+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $61.91 | -2,360 | 45.2K | -5% | -$146.1K |
| DM | 2022-03-14 | 2022-03-10+ | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +5,084 | 46.5K | +12% | — |
| D | 2021-12-07 | 2021-12-03 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +13.3K | 49.8K | +37% | — |
| D | 2021-12-07 | 2021-12-06 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $69.17 | -6,303 | 43.5K | -13% | -$436.0K |
| D | 2021-12-03 | 2021-12-02 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | $13.62 | +7,342 | 36.5K | +25% | +$100.0K |
| D | 2021-09-14 | 2021-09-13 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | F - Tax | $117.86 | -4,741 | 29.2K | -14% | -$558.8K |
| D | 2021-09-14 | 2021-09-10 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | GC, Sec | M - OptEx | — | +10.0K | 33.9K | +42% | — |
Purchase Sale Sale after option exercise All abbreviations